65,437 trials
Giant Cell Arteritis
Primary: Maximum Serum Concentration (Cmax) of TCZ — 197; 178 ug/mL
Coronary Artery Disease
Primary: Target Vessel Failure (TVF) — 11.38 percentage of participants
Pain · Vision Nearsighted
Primary: Number of Participants With Pain Score of Four or Greater. Score Range: 0-10, Higher Score Corresponds to More Pain. — 0 Participants
Crohn's Disease
Primary: Number of Subjects Achieving Response to Therapy, Defined as Reduction in the CDAI Score and in Inflammatory Markers CRP or FCP at Day 42. — 29; 16 Participants
Aortic Aneurysm, Abdominal
Primary: Number of Subjects With Treatment Success — 58 Participants
Venous Thrombosis · Neoplasms
Primary: PTS Assessment Completion — 17 Participants
Prostate Cancer · Oligometastases
Primary: Progression at 6 Months — 11; 7 Participants
Vaginal Atrophy
Primary: Vulvar Assessment Scale (VUAS) — 0.10; 0.20 score on a scale
Becker Muscular Dystrophy
Primary: Change From Baseline in Muscle Tissue PGC1alpha (AU) at 8 Weeks — 0.55; 0.86 AU — p=0.0434
Knee Osteoarthritis · Primary Total Knee Arthroplasty · Physical Therapy
Primary: Number of Participants Able to Hyperextend the Knee After Surgery — 4; 3 Participants
Aortic Aneurysm, Abdominal
Primary: The Primary Safety Endpoint is Defined as the Percentage of Subjects Who Experience a Major Adverse Event Within 30 Days of the Initial Procedure. — 4 Participants
Atrial Fibrillation
Primary: Number and Percentage of Participants With Esophageal Thermal Injury — 8; 5; 13 Participants — p=>.05
Complicated Intra-Abdominal Infection
Primary: Number of Participants Experiencing ≥1 Adverse Events (AEs) — 56; 13 Participants
Amyloidosis, Familial · Transthyretin Amyloidosis
Primary: Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR) — 91.0 percent reduction
Hydrocephalus
Primary: 50 Participants With Non-infection Within One Year — 1 Participants